Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.33 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.31 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.30 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.31 |
| ▸ | MERTK | Q12866 | 2/20 | 0.31 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9101017 | 0.99 | LMNA (0.35) | MEN1LMNAKMT2AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL9106602 | 0.82 | MEN1 (0.39) | MEN1LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL9108283 | 0.81 | MEN1 (0.40) | MEN1LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL18073749 | 0.79 | MEN1 (0.33) | MEN1LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL9912503 | 0.73 | KMT2A (0.43) | MEN1LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL9104257 | 0.73 | MERTK (0.36) | FLT3TYRO3MERTK | |
| Hydrochloric Acid SCHEMBL9105736 | 0.73 | KMT2A (0.40) | MEN1LMNAKMT2AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL9102432 | 0.72 | LMNA (0.42) | MEN1LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL9105291 | 0.71 | KMT2A (0.41) | MEN1LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL9107690 | 0.70 | LMNA (0.43) | MEN1LMNAKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9162992-B2 | Compounds and compositions for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2855438-A2 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | Galleon Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2013181217-A2 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | MTNR1B, CHRM3, ADRA2C | GAA 342/4885FLT3 3430/4885GLA 3428/4885 |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | PER2, SMPD4, NDUFB5 | GAA 563/4885FLT3 4636/4885GLA 2163/4885 |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, MTNR1B, NDUFB5 | GAA 530/4885FLT3 4741/4885GLA 2022/4885 |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | P2RX5, HRH2, ADRA2C | GAA 672/4885FLT3 1295/4885GLA 4559/4885 |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, SMPD4, NDUFB5 | GAA 563/4885FLT3 4636/4885GLA 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.